PMID- 34814581
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 0254-6450 (Print)
IS  - 0254-6450 (Linking)
VI  - 42
IP  - 9
DP  - 2021 Sep 10
TI  - [Cost-benefit analysis of the hepatitis B vaccination to prevent mother-to-child 
      transmission strategies in China, 1992-2019].
PG  - 1537-1545
LID - 10.3760/cma.j.cn112338-20210319-00226 [doi]
AB  - Objective: To make a cost-benefit analysis of the hepatitis B vaccination (HepB) 
      to prevent mother-to-child transmission (PMTCT) strategies in China, 1992-2019. 
      Methods: We built a decision analytic-Markov model to estimate the birth cohorts 
      of 1992-2019. The parameters in our model were referred from literature, 
      published yearbooks, and data from Chinese Center for Disease Control and 
      Prevention. We conducted a univariate sensitivity analysis to test the robustness 
      of the model. Results: For the 28 birth cohorts, the Chinese government has 
      invested 37.43 billion RMB Yuan in direct costs and 47.61 billion RMB Yuan in 
      societal costs on HepB vaccination and HBV prevention of mother to child 
      transmission (PMTCT). And we estimated that about 50 million chronic HBV 
      infections and 12.5 million premature deaths due to HBV-related diseases would be 
      averted. China would save 2.89 trillion RMB Yuan and 6.92 trillion RMB Yuan for 
      the direct and societal medical burden on HBV-related conditions. The direct and 
      societal net benefit was 2.85 trillion RMB yuan 6.87 trillion RMB yuan, 
      respectively. The direct and societal benefit-cost ratios (BCRs) were 77.21 and 
      145.29, respectively. Conclusion: The strategies of HepB vaccination for HBV 
      PMTCT prevention were cost-effective in China during 1992-2019.
FAU - Zheng, H
AU  - Zheng H
AD  - Department of National Immunization Program,Chinese Center for Disease Control 
      and Prevention, Beijing 100050, China.
FAU - Wang, F Z
AU  - Wang FZ
AD  - Department of National Immunization Program,Chinese Center for Disease Control 
      and Prevention, Beijing 100050, China.
FAU - Zhang, G M
AU  - Zhang GM
AD  - Department of National Immunization Program,Chinese Center for Disease Control 
      and Prevention, Beijing 100050, China.
FAU - Miao, N
AU  - Miao N
AD  - Department of National Immunization Program,Chinese Center for Disease Control 
      and Prevention, Beijing 100050, China.
FAU - Liang, X F
AU  - Liang XF
AD  - School of Medicine Jinan University, Guangzhou 510632, China.
FAU - Yin, Z D
AU  - Yin ZD
AD  - Department of National Immunization Program,Chinese Center for Disease Control 
      and Prevention, Beijing 100050, China.
LA  - chi
GR  - 11971375/National Natural Science Foundation of China/
GR  - 2018ZX10721202/National Science and Technology Major Project of China/
PT  - Journal Article
PL  - China
TA  - Zhonghua Liu Xing Bing Xue Za Zhi
JT  - Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
JID - 8208604
RN  - 0 (Hepatitis B Vaccines)
SB  - IM
MH  - China/epidemiology
MH  - Cost-Benefit Analysis
MH  - Female
MH  - *Hepatitis B/prevention & control
MH  - Hepatitis B Vaccines
MH  - Humans
MH  - *Infectious Disease Transmission, Vertical/prevention & control
MH  - Vaccination
EDAT- 2021/11/25 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/11/24 02:19
PHST- 2021/11/24 02:19 [entrez]
PHST- 2021/11/25 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.3760/cma.j.cn112338-20210319-00226 [doi]
PST - ppublish
SO  - Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Sep 10;42(9):1537-1545. doi: 
      10.3760/cma.j.cn112338-20210319-00226.